Author

Hong Mei

ShanghaiTech UniversityPrimary ORCID profile (0000-0002-8266-7073 · 2 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Hong MeiiD2 papers · Wuhan Children's Hospital

Biology Disciplines

Click to filter author papers

Molecular Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cell-cell communication· 1 Assay:CRISPR screen· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Organism:non-human primate· 1

Frequent Co-Authors

Alok K. Sharma· 1 shared Anastasia G. HenryiD· 1 shared Anthony A. EstradaiD· 1 shared Antonia Stepan· 1 shared Brian K. Fiske· 1 shared Carrie Markgraf· 1 shared Christopher Houle· 1 shared Christopher Royer· 1 shared

Activity by Year

2018-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Alok K. Sharma

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Surfaceome CRISPR Screen Identifies OLFML3 as a Rhinovirus-inducible IFN Antagonist

Hong Mei, Zhao Zha, Wei Wang, Yusang Xie, Yuege Huang, Wenping Li, Dong Wei, Xinxin Zhang, Jia Xie, Jia Liu

The paper identifies OLFML3 as a rhinovirus-inducible IFN antagonist using surfaceome CRISPR screening, showing its role in suppressing innate immunity.

Genome biology · Oct 22, 2021Peer-reviewedMolecular Biology

LRRK2 kinase inhibitors induce a reversible effect in the lungs of non-human primates with no measurable pulmonary deficits

Marco A.S. Baptista, Kalpana Merchant, Ted Barrett, Diane K. Bryce, Michael Ellis, Anthony A. Estrada, Matthew J. Fell, Brian K. Fiske, Reina N. Fuji, Paul Galatsis, Anastasia G. Henry, Sue Hill, Warren Hirst, Christopher Houle, Matthew E. Kennedy, , Todd B. Sherer

This study evaluates the lung effects of LRRK2 kinase inhibitors in non-human primates, finding reversible histopathological changes without pulmonary function deficits.

bioRxiv · Aug 15, 2018 · PreprintPharmacology & Toxicology